Heartflow, Inc. (HTFL) AI Stock Summary

Snapshot

HeartFlow is a fast-growing medical technology firm that uses AI to diagnose coronary artery disease. Revenue hit $176M in FY 2025, up 40% year-over-year, and gross margin is strong at 77%. However, the company loses money due to heavy spending on research and sales, resulting in a $116.8M net loss. It holds $176.8M in cash, but the burn rate leaves a cash runway of only 4.8 months. To support operations, the share count has ballooned, rising 484% in the last year.

What's Happening Right Now

• Thu 13th Aug '26 · Earnings: HeartFlow reported Q2 revenue of $64.1M, up 48% year-over-year, and raised its full-year 2026 revenue guidance to between $246M and $250M.
• Thu 9th Jul '26 · Product: The company launched Heartflow Plaque Staging, a new risk-stratification tool for coronary artery disease management, supported by clinical data presented at the SCCT 2026 meeting.

Ownership

Institutions hold 100.0%, insiders hold 1.8%.

Bottom Line

HeartFlow has impressive growth and a valuable product, but the financial structure is highly stressed. A cash runway of less than five months combined with massive share dilution creates significant risk. The company will likely need to raise more capital soon to survive, which could further dilute shareholders. This is a high-growth story with immediate solvency questions.